Beam Therapeutics (BEAM) Competitors $16.85 -0.01 (-0.06%) Closing price 04:00 PM EasternExtended Trading$17.05 +0.20 (+1.18%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, LEGN, RVMD, RYTM, and RNAShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "medical" sector. Beam Therapeutics vs. Its Competitors CRISPR Therapeutics Denali Therapeutics Editas Medicine Intellia Therapeutics Twist Bioscience Veracyte Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership. Which has higher earnings & valuation, BEAM or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M26.83-$376.74M-$4.50-3.74CRISPR Therapeutics$37.31M129.32-$366.25M-$5.43-9.77 Is BEAM or CRSP more profitable? Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Which has more volatility and risk, BEAM or CRSP? Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Do analysts prefer BEAM or CRSP? Beam Therapeutics presently has a consensus target price of $48.45, suggesting a potential upside of 187.56%. CRISPR Therapeutics has a consensus target price of $71.60, suggesting a potential upside of 34.97%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47 Do insiders and institutionals have more ownership in BEAM or CRSP? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor BEAM or CRSP? In the previous week, CRISPR Therapeutics had 8 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.04 beat CRISPR Therapeutics' score of 1.02 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-3.747.3622.5622.49Price / Sales26.83398.26463.84113.07Price / CashN/A44.6737.7359.36Price / Book1.638.0910.046.68Net Income-$376.74M-$54.08M$3.27B$265.59M7 Day Performance5.25%2.25%3.17%3.42%1 Month Performance-19.11%3.41%4.34%1.09%1 Year Performance-35.32%18.61%44.12%23.84% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics2.046 of 5 stars$16.85-0.1%$48.45+187.6%-35.9%$1.71B$63.52M-3.74510Positive NewsCRSPCRISPR Therapeutics3.5235 of 5 stars$57.59-3.6%$71.60+24.3%+11.0%$5.24B$37.31M-10.61460Positive NewsAnalyst UpgradeDNLIDenali Therapeutics4.2981 of 5 stars$14.82+0.8%$33.62+126.8%-37.5%$2.17B$330.53M-5.29430Positive NewsEDITEditas Medicine4.2551 of 5 stars$2.73-9.9%$5.10+86.8%-30.1%$245.48M$32.31M-0.96230News CoverageNTLAIntellia Therapeutics4.5455 of 5 stars$10.73-2.4%$29.05+170.8%-50.2%$1.15B$57.88M-2.29600Positive NewsTWSTTwist Bioscience3.9454 of 5 stars$28.02-0.4%$49.40+76.3%-39.7%$1.69B$312.97M-19.32990Positive NewsVCYTVeracyte2.3931 of 5 stars$30.07-0.5%$40.90+36.0%-10.6%$2.37B$445.76M91.12790LEGNLegend Biotech3.8863 of 5 stars$37.45-0.1%$72.38+93.3%-39.1%$6.88B$627.24M-42.562,609News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.318 of 5 stars$36.45+0.4%$69.54+90.8%-12.7%$6.81B$11.58M-8.10250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.5322 of 5 stars$98.09+0.5%$101.57+3.5%+115.7%$6.52B$130.13M-32.59140Positive NewsInsider TradeRNAAvidity Biosciences2.9832 of 5 stars$44.48-4.3%$67.00+50.6%+9.4%$5.72B$10.73M-12.49190Positive News Related Companies and Tools Related Companies CRSP Alternatives DNLI Alternatives EDIT Alternatives NTLA Alternatives TWST Alternatives VCYT Alternatives LEGN Alternatives RVMD Alternatives RYTM Alternatives RNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access